Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Undisclosed
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $954.0 million
Deal Type : Collaboration
Lindy Bio Enters Collaboration Agreement with Novartis for Drug Delivery Innovation
Details : The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous injections using Lindy Bio proprietary technology.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $20.0 million
August 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $954.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?